TSTickerStar
Company alerts/APUS
APUS company alerts

APUS updates worth following

TickerStar monitors official filings, investor releases, earnings, and call updates for APUS. Subscribe to APUS alerts to receive concise, source-linked alerts when TickerStar detects a meaningful company update.

Official-source feed

Recent APUS alert previews

TickerStar filters routine noise and surfaces investor-relevant filings, releases, earnings, and call updates.

Company updateOfficial company source

Apimeds Pharmaceuticals US Sets 2026 Annual Meeting for December 23

Apimeds Pharmaceuticals US, Inc. has filed its definitive proxy statement for the 2026 Annual Meeting of Stockholders scheduled for December 23, 2026 at 9:30 a.m. Eastern Time as a completely virtual meeting. Stockholders of record as of November 20, 2026 will vote on the election of four directors, ratification of Kreit & Chiu CPA LLP as independent auditor for fiscal year 2026, and an adjournment proposal. The Board unanimously recommends voting FOR all proposals.

Read source-backed brief
EarningsOfficial company source

Apimeds Pharmaceuticals US Reports Q3 2026 Results

Apimeds Pharmaceuticals US reported Q3 2026 revenue of $2.89 million and operating income of $2.0 million, its first full quarter of revenue from technology services following the disposal of its former biopharmaceutical subsidiary on July 14, 2026. Net income was $33.6 million, or $19.13 per basic share and $7.68 per diluted share, which includes a $25.26 million unrealized gain on digital assets. The company disclosed substantial doubt about its ability to continue as a going concern due to a $10.5 million sen...

Read source-backed brief
SEC filingSEC filing

APUS 10-Q filed 2026-11-16 | Key takeaways

APUS filed its 10-Q; the most relevant disclosure change is expanded Discontinued operations and deconsolidation: Lokahi Therapeutics Inc. was deconsolidated on July 14, 2026 upon merger with Glucotrack, Inc.; company received 37,884 Glucotrack common shares and rights to 2,269,100 Series A preferred shares (as converted), measured at $962,935 total fair value; gain on de. Customer concentration: Two customers (Customer A and Customer B) represented 100% of revenue; Two customers represented 100% of accounts_rec...

Read source-backed brief